Science & Enterprise subscription

Follow us on Twitter

  • Genny Cream for me, if I were there https://t.co/BQcWbr7yLh
    about 2 hours ago
  • As the race to produce and distribute Covid-19 vaccines intensifies, financing of this global public health project… https://t.co/pyDX0IWnCs
    about 7 hours ago
  • New post on Science and Enterprise: Infographic – Public Money Funds Covid-19 Vaccines https://t.co/1D2XLhUi4Z #Science #Business
    about 7 hours ago
  • Excellent analysis. Real example: a colleague I hired at Science mag is leaving her job to get a grad degree in IT. https://t.co/c0qnYW025H
    about 10 hours ago
  • Two biotechnology companies are collaborating on using the gene editing technique Crispr to create engineered immun… https://t.co/4lK4qD5p6m
    about 1 day ago

Please share Science & Enterprise

Venture Investor to Back Underserved Tech Entrepreneurs

Smartphones in business meeting

An investment company is offering training and seed funds to women technology entrepreneurs, and those in LGBTQ, racial, and ethnic minority communities. . . . → Read More: Venture Investor to Back Underserved Tech Entrepreneurs

Venture-Backed Start-Ups to Get Small Biz Loans

Investing monitor

An industry group says rules for loans to small companies hard-hit by Covid-19 are changed to allow these loans for more start-ups funded by venture capital. . . . → Read More: Venture-Backed Start-Ups to Get Small Biz Loans

Microsoft Launches $1 Billion Climate Fund

La Tuna fire 2017

Microsoft Corp. plans to invest $1 billion over the next four years to create technologies for removing carbon from the atmosphere. . . . → Read More: Microsoft Launches $1 Billion Climate Fund

Patent Set for Heart Tissue Regeneration Drug

A drug developed by MDI Biological Laboratory that stimulates growth of heart tissue to fix damage from heart attacks is scheduled to receive a U.S. patent. . . . → Read More: Patent Set for Heart Tissue Regeneration Drug

RNA Technology Licensed for Cystic Fibrosis Therapy

Two biotechnology companies are collaborating on treatments for cystic fibrosis that use genetic material to address underlying causes of the inherited disease. . . . → Read More: RNA Technology Licensed for Cystic Fibrosis Therapy

University Lab Spins-Off Fertility Testing Company

Katie Brenner (Bryce Richter, Univ. of Wisconsin-Madison)

29 April 2016. A new company is taking shape that aims to make it easier for women to get pregnant, based on research at a biochemistry lab at University of Wisconsin. BluDiagnostics, in Madison, founded by postdoctoral research Katie Brenner in the lab of biochemistry professor . . . → Read More: University Lab Spins-Off Fertility Testing Company

Biotechs to Develop Antibody Therapies, Explore Merger

Downtown Vancouver (Magnus Larsson, Flickr)

8 January 2016. Two biotechnology companies in Vancouver agreed to collaborate on developing antibody treatments for cancer, with an option to merge their enterprises later on. The deal calls for Zymeworks Inc. to make an undisclosed equity investment in Kairos Therapeutics Inc. Zymeworks is also receiving $US 61.5 . . . → Read More: Biotechs to Develop Antibody Therapies, Explore Merger

Illumina Adds $40M for Genomic Accelerator Start-Ups

(Genome.gov)

26 February 2015. Illumina Inc., a developer of genomic analysis systems, is adding $40 million for investments in new enterprises based on genomic science that graduate from its accelerator program. The additional financing is provided by Viking Global Investors, an equity and hedge fund investment company in Greenwich, Connecticut.

The Illumina Accelerator . . . → Read More: Illumina Adds $40M for Genomic Accelerator Start-Ups

Cancer Therapy Spin-Off Formed with $45M Funding

T-cell (NIAID/NIH)

22 January 2015. Autolus Ltd., a new enterprise developing engineered immune-system cells for treating cancer, is being formed in London, with £30 million ($45.4 million) in early financing. The company is founded and commercializing research by Martin Pule, a hematologist at University College London.

Pule, who serves as Autolus’s chief scientist, . . . → Read More: Cancer Therapy Spin-Off Formed with $45M Funding

Portfolio Model Proposed for Funding Alzheimer’s Research

(National Institute of Drug Abuse)

18 June 2014. Financial and biomedical researchers at Massachusetts Institute of Technology, University of California in Santa Barbara, and the biotechnology company Genentech outlined a different approach to funding research on Alzheimer’s disease that supports multiple simultaneous studies addressing various drug targets. The team led by MIT finance . . . → Read More: Portfolio Model Proposed for Funding Alzheimer’s Research